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ABSTRACT: Macrocyclic monoacyl lathyrane derivatives bearing a benzoyl moiety were previously found to be strong ABCB1
modulators. To explore the eﬀects of diﬀerent substituents of the aromatic moiety, 14 new compounds (1.1−1.7, 1.10, and 2.1−
2.4) were prepared from jolkinol D (1), obtained from Euphorbia piscatoria, and from jolkinodiol (2), its hydrolysis derivative.
Compounds 1.8 and 1.9, having aliphatic moieties, were also obtained. The reversal of ABCB1-mediated MDR was evaluated
through functional and chemosensitivity assays on the human ABCB1-gene-transfected L5178Y mouse T-lymphoma cell line.
Structure−activity relationships showed that addition of electron-donating groups to the aromatic moiety improved the activity.
The eﬀects on the ATPase activity of the strongest modulator (1.3) and the inactive jolkinol D (1) were also investigated and
compared. Moreover, in the chemosensitivity assay, most of the compounds interacted synergistically with doxorubicin.
Compounds 1.1−1.10 and 2.1−2.4 were further assessed for their collateral sensitivity eﬀect against the human cancer cells:
EPG85−257 (gastric) and EPP85−181 (pancreatic), and the matching drug-selected cells EPG85-257RDB, EPG85-257RNOV,
EPP85-181RDB, and EPP85-181RNOV. The most promising ones (1.8 and 1.10) along with compound 3, previously selected,
were investigated as apoptosis inducers. The compounds were able to induce apoptosis through caspase-3 activation, with
signiﬁcant diﬀerences being observed between the parental and resistant cells.
Throughout the world, cancer continues to be a leadingcause of mortality.1 Despite the number of advances in
this ﬁeld, the development of resistance to anticancer drugs
constitutes one of the main problems for a successful treatment.
In the course of chemotherapy, multidrug resistance (MDR) is
likely to occur, and as a result, tumors fail to respond to a broad
spectrum of structurally and mechanistically diverse anticancer
agents.2,3 A panoply of cellular resistance mechanisms related
with an MDR cancer phenotype have been identiﬁed; one of
the most widely studied involves the transmembrane ABC
transporter P-glycoprotein (P-gp/ABCB1).4−6 In normal cells,
this eﬄux pump takes part in the natural detoxifying system,
recognizing xenobiotics and extruding them from the cytosol.
However, in cancer cells, ABCB1 overexpression causes a
reduction of the cytosolic concentration of the anticancer agent.
This will lead to a treatment failure resulting in cross-resistance
to several cytotoxic drugs, such as cisplatin, colchicine,
vinblastine, paclitaxel, doxorubicin, and protein kinase inhib-
itors.6 The improvement of chemotherapies targeted to
overcome cancer MDR holds promise for a selective and
eﬃcient cancer treatment. Promising strategies to accomplish
that purpose depend on the research of molecules capable of
lessening the ABCB1 drug eﬄux, and the discovery of
compounds with collateral sensitivity activity.7,8
The collateral sensitivity eﬀect was ﬁrst observed in bacteria,
but nowadays it is being used as a powerful asset to study
cancer MDR.8,9 In resistant cancer cells, each genomic,
proteomic, or metabolomic alteration that conferred advantages
during chemotherapeutic pressure might be at the same time a
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way to create vulnerabilities. The collateral sensitivity eﬀect
approach takes advantage of these vulnerabilities, converting
them into new therapeutic targets.8,10,11 Consequently, drug-
resistant phenotypes can be more sensitive to alternate agents
than the original parental cell line.8,11 As a result, highly
selective compounds can be found and characterized.
Anticancer drug discovery programs are increasing their
interest in natural products.12 Nature presents a vast chemical
space that was selected through evolution to interact with a
wide range of biological targets. Therefore, it is not surprising
why natural compounds and their derivatives have become
eﬀective anticancer drugs.13 Owing to the fast pace of
development of drug resistance, a growing chemical space is
needed. In this regard, Euphorbia macrocyclic diterpenoids of
the jatrophane- and lathyrane-type have shown signiﬁcant
MDR reversal activity, by ABCB1 modulation and/or by
selective targeting of MDR cancer cells. These promising
results guide us to the development of in silico studies, and
structure activity studies for optimizing their structures in order
to develop an eﬀective MDR reversal agent.14−19 Despite this
progress, understanding their anti-MDR mode of action is still
lacking.
In a previous report, we discussed a small library of jolkinol
D derivatives in order to study the impact of structural
modiﬁcations on ABCB1 eﬄux modulation. It was concluded
that the presence of an aromatic moiety improved the
inhibition of this eﬄux pump at noncytotoxic doses.20
Moreover, these derivatives were evaluated for their collateral
sensitivity eﬀects, of which jolkinoate L (3, Figure 1) displayed
an interesting MDR-selective antiproliferative activity.21 In the
sequence of this anti-MDR development project, we optimized
jolkinol D (1) and jolkinodiol (2) scaﬀolds by generating a new
set of derivatives (1.1−1.10 and 2.1−2.4) in order to obtain a
higher MDR reversal eﬀect. This was assessed through the
combination of ABCB1 modulation and collateral sensitivity
eﬀects. Thus, compounds 1.1−1.10 and 2.1−2.4 were tested
for their ability to modulate the drug eﬄux activity of ABCB1
and to resensitize MDR cells to doxorubicin in drug
combination studies, using ABCB1-transfected mouse T-
lymphoma L5178Y cells. The type of interaction with the
ATPase function of ABCB1 was also investigated for the parent
molecule (1) and the strongest modulator (1.3). The MDR-
selective antiproliferative activity was assayed using the human
tumor gastric (EPG85-257) and pancreatic (EPP85-181) cell
models (drug-sensitive and drug-resistant sublines), well
characterized for MDR.21−23 The most promising derivatives
(1.8, 1.10), and jolkinoate L (3), were investigated for their
potential as apoptosis inducers.
■ RESULTS AND DISCUSSION
Chemistry. The previous structure−activity relationship
(SAR) analysis of jolkinol D (1) derivatives showed that
ABCB1 eﬄux modulation was enhanced when an aromatic
ester moiety was added to the lathyrane scaﬀold.20 However,
the role of aromatic electronic eﬀects as well as hindrance
eﬀects on ABCB1 eﬄux activity was still to be investigated. As a
result, a new set of derivatives (1.1−1.10 and 2.1−2.4) was
generated. Jolkinoates J−T (1.1−1.7) were obtained by
reaction of jolkinol D (1), isolated from Euphorbia piscatoria
Ait. (Euphorbiacae),20 with the respective aroyl chlorides in the
presence of CH2Cl2, TEA, and DMAP (Scheme 1). In parallel,
to study the role of the free hydroxy group at C-15, jolkinolates
A−D (2.1−2.4) were prepared using jolkinodiol (2)20 as
parent molecule (Scheme 1). Moreover, an adamantane
derivative (1.8) and two carbonate esters, one aliphatic (1.9)
and one aromatic (1.10), were also synthesized (Scheme 2),
using silver triﬂate24 as catalyst. The structures of the
derivatives were assigned by 1D and 2D NMR and HRMS
data. The 1H and 13C NMR data of compounds 1.1−1.10 and
2.1−2.4 were compared with those of jolkinol D (1) and
jolkinodiol (2), respectively. As expected, the main diﬀerences
were found for C-3 and H-3, which showed paramagnetic
eﬀects in carbon and proton chemical shifts (ΔδC ≅ 0.2−6.4
and ΔδH ≅ 1.1−1.9 ppm), due to the presence of the ester
function. The β-carbons of the acyl derivatives (C-2 and C-4)
also showed the anticipated diamagnetic eﬀects (ΔδC ≅ 0.8
and 0.6−1.4 ppm, respectively).
ABCB1-MDR Reversal Activity. In order to compare with
the previous results, the same experimental design20 was
followed. The antiproliferative activity of the compounds was
assayed against the parental mouse T-lymphoma cells (L5178Y-
PAR), and the ABCB1-transfected counterpart (L5178Y-
MDR), using the MTT assay. The derivatives 1.1−1.10 and
2.1−2.4 did not show a signiﬁcant antiproliferative proﬁle (IC50
> 19 μM) for both cell lines (Table S1).
Modulation of ABCB1 eﬄux was tested using the standard
rhodamine-123 functional assay. Whether a compound
modulates ABCB1 eﬄux or not is given by the ﬂuorescence
activity ratio (FAR). This ratio represents the accumulation of
rhodamine-123 between L5178Y-MDR and L5178Y-PAR cells.
Modulation of ABCB1 is considered to occur when FAR values
are higher than one. Strong modulation of this transporter
occurs when this ratio is higher than 10.25 The derivatives 1.1−
1.10 and 2.1−2.4 were tested at 2 and 20 μM (nontoxic
concentrations), and verapamil, a standard modulator, was used
as positive control. When tested at 20 μM, all the lathyrane
derivatives (1.1−1.10; 2.1−2.4) caused a strong impairment of
ABCB1 eﬄux activity, with FAR values ranging from 9.9 to 41.5
(Table 1). The strongest modulators of this library were
depicted based on the 2 μM data (Table 1). Thus, the most
eﬃcient modulators were the jolkinol D derivatives 1.2, 1.3,
1.5−1.8, and 1.10 and the jolkinoldiol derivative 2.1 (FAR
values from 10.8 to 33.3). These results are interesting because
the ABCB1 reversal activity of verapamil (22 μM) was 12.5.
Structure−Activity Relationships. The K-means cluster-
ing algorithm was used to highlight some of the possible
relations between ABCB1 modulatory activity and the
calculated physicochemical features. As a result, four groups
sharing a high degree of similarity, in terms of physicochemical
properties and activity at 2 μM, were generated (Figure 2). The
ﬁrst cluster grouped the derivatives with the bulkier
Figure 1. Jolkinoate L (3).
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substituents (1.4, 1.6, 1.7, 1.8, and 2.4), therefore showing the
highest MW, MV, logP, MR, and ASA values (Figure 2). The
strongest ABCB1 modulators 1.2, 1.3, and 1.5 were grouped
mainly due to the FAR values, since their physicochemical
properties are shared by compounds in clusters I and III
(Figure 2). Cluster III comprised the jolkinodiol derivatives
2.1−2.3 as well as compounds 1.1 and 1.10. Jolkinocarbonate
A (1.9) occupied cluster IV. Nevertheless, contrary to what was
described for the ﬁrst set of jolkinol D derivatives,20 no
signiﬁcant correlations were found between the computed
physicochemical properties and ABCB1 modulatory activity.
This can be suggestive of a stronger role of the sum of other
structural aspects, than the contribution of a single
physicochemical property. In fact, a recent in silico study,
through 2D and 3D Q(quantitative)SAR, concluded that the
conformation of the lathyrane macrocyclic scaﬀold and its
substitution pattern (related to steric and electrostatic factors)
were the main determinants for the ABCB1 modulation
activity.19
Therefore, to investigate the former observations, attention
was focused on the SAR of esters containing the aromatic
moiety; in this way, we compared the previous results20 with
those described herein. Thus, in comparison to jolkinoate I,20
bearing an unsubstituted aroyl moiety (FAR = 24.2), the
introduction of triﬂuormethyl, an electron-withdrawing group,
at the meta or para positions of the benzene moiety, lead to a
Scheme 1. Preparation of Jolkinoates N−T (1.1−1.7) and Jolkinolates A−D (2.1−2.4)a
aReagents and conditions: 1 equiv of jolkinol D (1); 1 equiv of jolkinodiol (2); (i) Respective aroyl chlorides; TEA, CH2Cl2, DMAP (cat.), reﬂux 60
°C.
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Scheme 2. Preparation of Jolkinoate U (1.8) and Jolkinocarbonates A and B (1.9−1.10)a
aReagents and conditions: 1 equiv of jolkinol D (1); (a) Respective chlorides; AgOTF (1 mol %), CH2Cl2, reﬂux 60 °C.
Table 1. Modulation of ABCB1-Mediated Rhodamine-123 Eﬄux by Jolkinol D Derivatives 1.1−1-10 and Jolkinodiol
Derivatives 2.1−2.4
aFAR = (L5178Y-MDRFL‑1treated/L5178Y-MDRFL‑1control)/(L5178Y-PARFL‑1treated/L5178Y-PARFL‑1control). FL-1: mean ﬂuorescence intensity of the
cells. Verapamil (22 μM) FAR = 12.5. DMSO (2%) FAR = 0.87.
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decreased eﬄux modulatory eﬃciency [(2.5-fold) FAR = 9.3
and 9.4, respectively to jolkinoate L20 and 1.4]. Likewise,
jolkinocarbonate B (1.10; FAR = 10.8) with a phenyl
substituent, lost modulatory ability in comparison to jolkinoate
I. Jolkinoate N (1.1; FAR = 2.2), displaying an m-methyl group,
was nearly inactive. However, jolkinoate J,20 possessing this
moderate electron-donating group at the para position, retained
a strong modulatory character (FAR = 21.1). The eﬀects of a
strong electron-donating group were investigated by using the
methoxy group; nevertheless, diﬀerences in activity were not
signiﬁcant. Incorporation of this group at the ortho (1.3; FAR =
33.3) and para (jolkinoate K; FAR = 28.1)20 positions seemed
to have a slightly higher electronic inﬂuence due to the
resonance eﬀects than its regioisomer at the meta position (1.2;
FAR = 26.1). Moreover, jolkinoate R (1.5; FAR = 28.6),
bearing a cinnamoyl moiety, was also among the strongest
modulators, suggesting that the aromatic conjugated system is a
contributor toward ABCB1 modulation.
The potential steric hindrance on ABCB1 eﬄux modulation
was studied by inclusion of bulky groups such as naphthoyl
(1.6; FAR = 11.9), biphenoyl (1.7; FAR = 11.6), and
adamantoyl (1.8; FAR = 12.6). The 2-fold reduction of
modulatory eﬃciency, when compared to jolkinoate I (FAR =
24.2),20 suggests that introduction of a bicyclic moiety
potentiates steric clashes within the drug-binding pocket of
ABCB1, independently from its aromatic nature. Similar
observations were found by Jiao and co-workers, which veriﬁed
that lathyrol derivatives with 1-naphthylacetyl or phenylacetyl
substituents lost ABCB1 modulatory ability.26
Furthermore, some derivatives of jolkinodiol (2) were
included to test the role of a free hydroxy group at C-15.
Jolkinolate A (2.1), bearing a 3-methoxybenzoyl moiety at C-3,
showed a 2-fold loss in eﬃcacy in comparison to jolkinoate O
(1.2), where the hydroxy group at C-15 is acetylated. The same
tendency was observed for the jolkinoldiol derivatives 2.2, 2.3,
and 2.4 in comparison to their respective counterparts 1.4, 1.6,
Figure 2. Cluster analysis of compounds 1.1−1.10 and 2.1−2.4. Box and whiskers plot representing each grouping variable: FAR values (2 μM),
molecular weight (MW), molecular volume (MV), logP prediction developed at Molinspiration (logP), molar refractivity (MR), topological polar
surface area (TPSA), and accessible solvent area (ASA). Physicochemical properties were calculated using JME molecular editor, version July 2016,
http://www.molinspiration.com/jme.
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and 1.7 (Table 1). Thus, the presence of the acetyl group at C-
15 as a hydrophobic center or hydrogen-bond acceptor moiety
might be more important for recognition/interaction with
ABCB1 than the presence of a hydrogen-bond donor. These
ﬁndings are in accordance with the in-house pharmacophore
model, based on macrocyclic diterpenoids and other ABCB1
inhibitors, in which the recognition pattern contains three
hydrophobic moieties and one hydrogen-bond acceptor
group.14
In conclusion, with this SAR study a favorable optimization
for jolkinoates as ABCB1 modulators was achieved. Benzoyl
moieties with electron-donating groups should increase the
electrostatic interactions and π-stacking at the drug-binding
pocket of ABCB1, resulting in a more powerful ABCB1 eﬄux
modulation.
Eﬀects on the ATPase Activity of ABCB1. ATP
hydrolysis is linked with the ABCB1 eﬄux activity.27,28 The
way how compounds aﬀect this catalytic activity can give
insights about their properties as substrate or inhibitor.
Therefore, the eﬀects on the ATPase activity of this membrane
transporter were evaluated for the parent compound jolkinol D
(1) and the most active modulator of this set of lathyranes,
jolkinoate P (1.3). This activity was assessed through the
production of inorganic phosphate directly resulting from the
ATP hydrolysis of human ABCB1 expressed in puriﬁed insect
membrane vesicles (Sf9). Vanadate is a phosphate analogue
that inhibits ABCB1 ATPase activity; therefore, the results
obtained are presented as the vanadate sensitive ATPase
activity. This ATPase experiment is composed of two
complementary assays. The activation assay classiﬁes com-
pounds as stimulators or inhibitors of the baseline vanadate
sensitive ATPase activity. The inhibition assay, performed in
the presence of a known ABCB1 activator, is used to
characterize eﬄux inhibitors (or slowly transported substrates)
through the decrease of verapamil-stimulated vanadate-sensitive
ATPase activity. Verapamil (40 μM) and cyclosporin A (40
μM) were used as positive controls in the activation and
inhibition assays, respectively. Jolkinol D (1) and jolkinoate P
(1.3) were tested in a dose-dependent manner, and the eﬀects
were shown as the relative ATPase activity, in which the
stimulated vanadate-sensitive ATPase activity is taken as 100%
and the baseline vanadate-sensitive ATPase activity as 0%.
Jolkinol D (1) enhanced the basal ATPase activity with 66−
87%, though this stimulation was not dose dependent (Figure
3A, activation assay). These ﬁndings indicate that compound 1
interacts with the membrane transporter ABCB1. Concerning
the verapamil-stimulated ATPase activity, jolkinol D (1)
showed an inhibitory eﬀect of 14−40%, in the range 3.13−
12.5 μM (Figure 3A, inhibition assay). At higher concentrations
(25−100 μM), compound (1) showed 9−33% stimulation of
the verapamil-stimulated ATPase activity (Figure 3A, inhibition
assay). The results from this ATPase assay suggest jolkinol D
(1) to be a transported substrate of ABCB1, which at some
concentrations can aﬀect verapamil transport (inhibition or
stimulation). Nevertheless, it should be noted that jolkinol D
(1) did not aﬀect ABCB1 eﬄux at 2 or 20 μM.20
Interesting results were obtained with the strong modulator
jolkinoate P (1.3). The direct interaction with ABCB1 is shown
through the activation of the ATPase activity (Figure 3B,
activation assay). This activation occurred to a lower extent
compared to jolkinol D (1). Moreover, at higher doses (>50
μM), jolkinoate P (1.3) inhibited ABCB1 ATPase activity. This
type of dose-dependent activation of ATPase activity at low
concentrations and inhibition at higher concentrations was
observed for several compounds.29,30 Recently, a conforma-
tionally gated model of drug-induced activation of ABCB1-
mediated ATP hydrolysis was established to study this issue.30
According to this model, when verapamil occupies the H-site of
the ABCB1 drug-binding pocket, ATP hydrolysis and transport
are maximized at low concentrations of verapamil. When
verapamil is present in high concentrations, it occupies both the
H-site and a low aﬃnity binding site; due to this, the protein is
stabilized into an “intermediate” conformation that prevents
ATP from driving ABCB1 to the ‘‘closed” conformation.
Consequently, the verapamil transport and verapamil-stimu-
lated ATP hydrolysis are reduced. These ﬁndings might help to
understand the jolkinoate P (1.3) dose eﬀect on the ABCB1
ATPase activity.
When tested concomitantly with a second substrate,
jolkinoate P (1.3) was able to diminish the verapamil-
stimulated ATPase activity, with a complete inhibition at 1.56
and 25 μM (Figure 3B, inhibition assay). This indicated that
jolkinoate P (1.3) was capable of ceasing the transport of
verapamil, through direct interaction with ABCB1. Moreover,
the inhibition assay also suggested jolkinoate P (1.3) to elicit a
biphasic dose response on the ABCB1 ATPase. This biphasic
nature was observed for some compounds and might be
attributed to the polyspeciﬁcity of ABCB1 drug-binding sites.31
Verapamil and rhodamine-123 have diﬀerent binding sites
within the drug-binding pocket of ABCB1.32,33 Relating the
results obtained in this work, it can be suggested that
compound 1.3 might act as a modulator and/or a slowly
Figure 3. Eﬀects of (A) jolkinol D (1) and (B) jolkinoate P (1.3) on
ABCB1 ATPase activity. Activation assay: tests the eﬀect on the basal
ATPase activity. Inhibition assay: tests the eﬀect on drug-stimulated
ATPase activity, measured in the presence of verapamil (40 μM).
Results are expressed as the mean ± SD. The eﬀects of compounds are
shown as the relative ATPase activity, in which the verapamil-
stimulated vanadate-sensitive ATPase activity is taken as 100% and the
baseline vanadate-sensitive ATPase activity as 0%.
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transported substrate aﬀecting the transport of these two
molecules.
Chemosensitization: Reversion of Drug-Induced Re-
sistance. In order to test if the lathyrane derivatives would
turn L5178Y-MDR cells more susceptible to anticancer drug
action, their combinations with doxorubicin were tested. The
nature of the drug interactions was determined by the
combination index (CI) as synergistic, additive, or antagonistic
(Table 2).34,35 Apart from jolkinoates R (1.5) and U (1.8), and
jolkinocarbonate A (1.9), that showed an antagonistic eﬀect on
the combination assay (CI = 1.11−2.02, Table 2), the
remaining derivatives improved the cytotoxicity of doxorubicin
synergistically (CI = 0.20−0.84). The modulators were able to
restore sensitivity to doxorubicin by reversing the ABCB1-
MDR phenotype.
Collectively the results from the transport (Table 1) and
drug combination assays (Table 2) showed that the tested
resistance modulators were able to aﬀect ABCB1 eﬄux activity
and to restore sensitivity to doxorubicin (except compounds
1.5, 1.8, and 1.9). This is an interesting ﬁnding because the
cytotoxic eﬃcacy of doxorubicin is known to be aﬀected by
ABCB1 activity.6,36 Moreover, it is interesting to note that,
although jolkinoates R (1.5) and U (1.8) were strong ABCB1
modulators at 2 μM, they displayed antagonistic eﬀects in the
combination experiments. These compounds might be
targeting other cellular pathways and, thus, may antagonize
the doxorubicin eﬀect by competing or inhibiting its targets,
independently from interaction with ABCB1.
Conversely, jolkinol D (1), a non-ABCB1 modulator,
showed a synergistic eﬀect with doxorubicin.20 Recalling the
nature of interaction with ATPase, jolkinol D (1) was qualiﬁed
as a transported substrate, and this result might contribute to
explaining why the combination between this nonmodulator
and the cytotoxic drug showed a synergistic nature.20
Therefore, this compound might have more aﬃnity or compete
with doxorubicin for ABCB1 transport, suggesting accumu-
lation of doxorubicin to the detriment of jolkinol D (1) eﬄux.
Collateral Sensitivity Eﬀect. In a preceding study, some
jolkinol D derivatives were assessed for their potential selective
antiproliferative activity against parental gastric (EPG85-257)
and pancreatic (EPP85-181) human cancer cells and their drug-
resistant counterparts, selected against mitoxantrone (RNOV)
or daunorubicin (RDB), respectively, using a proliferation
assay.21 Most of those derivatives exhibited selective anti-
proliferative activity eﬀects toward the EPG85-257RDB cell
line. However, jolkinoate L (3) showed a remarkable ability to
target diﬀerent cellular contexts with concomitant high
antiproliferative activity.21 As a continuation of this develop-
ment program, herein compounds 1.1−1.10 and 2.1−2.4 were
investigated for their potential collateral sensitivity eﬀect on the
same cancer entities (Tables S2 and S3, Supporting
Information).
The MDR-selective activity was assessed by the relative
resistance ratio (RR = IC50(resistant)/IC50(parental)). RR < 1
indicates that the compound kills MDR cells more eﬀectively
than parental cells, but if RR < 0.5, a collateral sensitivity eﬀect
is taking place.10 The cytotoxic agents etoposide and cisplatin
were used as positive controls. The antiproliferative activity and
collateral sensitivity eﬀects of compounds 1.1−1.10 and 2.1−
2.4 are shown as a heat map table (Table 3). This
representation enables the identiﬁcation of compounds that
show MDR-selective activity at a determined IC50 level. Most of
the derivatives were highly eﬀective toward the resistant gastric
cell lines, exhibiting an antiproliferative activity comparable to
the positive controls cisplatin and etoposide (Table 3, Table S2,
Supporting Information). The collateral sensitivity eﬀect (RR ≤
0.5) was mostly observed for EPG85-257RDB cells, which are
characterized by ABCB1 overexpression.37 With respect to
EPG85-257RNOV cells, the best results were obtained for
Table 2. Drug Combination Experiments in ABCB1-
Transfected Mouse T-Lymphoma Cells (L5178Y-MDR)
Combination with
Doxorubicin Ratioa CI ± SDb Interaction
Jolkinoate O (1.2) 25:1 0.84 ± 0.14 moderate synergism
Jolkinoate P (1.3) 10:1 0.09 ± 0.03 very strong
synergism
Jolkinoate R (1.5) 50:1 1.13 ± 0.37 slight antagonism
Jolkinoate S (1.6) 400:1 0.06 ± 0.02 very strong
synergism
Jolkinoate T (1.7) 100:1 0.32 ± 0.08 synergism
Jolkinoate U (1.8) 15:1 1.11 ± 0.37 slight antagonism
Jolkinocarbonate A (1.9) 5:1 1.22 ± 0.28 moderate
antagonism
Jolkinocarbonate B (1.10) 18:1 0.50 ± 0.07 synergism
Jolkinolate A (2.1) 50:1 0.38 ± 0.16 synergism
Jolkinolate C (2.3) 200:1 0.20 ± 0.05 strong synergism
aData are shown as the best combination ratio of the tested
compounds and doxorubicin. bCombination index (CI) values are
mean ± standard deviation (SD) for an inhibitory concentration of
50% (IC50). CI < 0.1: very strong synergism; 0.1 < CI < 0.3: strong
synergism; 0.3 < CI < 0.7: synergism; 0.7 < CI < 0.9: moderate to
slight synergism; 0.9 < CI < 1.1: nearly additive; 1.10 < CI < 1.45:
moderate antagonism; 1.45 < CI < 3.30: antagonism.34,35 Compounds
1.1, 1.4, 2.2, and 2.4 are not assayed due to IC50 > 80 μM.
Table 3. Heat Map Table Summarizing the Antiproliferative
and Collateral Sensitivity Results against Gastric Carcinoma
Cells (EPG85-257P, EPG85-257RNOV, and EPG85-
257RDB) and Pancreatic Carcinoma Cells (EPP85-181P,
EPP85-181RNOV, and EPP85-181RDB)a
aThis representation permits identifying compounds that show MDR-
selective activity at a determined IC50 sevel. Collateral sensitivity values
(RR < 0.5) are shown.
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compounds 1.1, 1.4, 1.8, 1.9, 1.10, and 2.3, which showed IC50
values lower than 10 μM (Table 3, Table S2), but only
derivatives 1.4 and 2.3 showed a collateral sensitivity eﬀect (RR
< 0.5). Nevertheless, no structure−activity relationships could
be inferred for these cell lines. Based on the IC50 and RR values
(Table 3, Table S2), jolkinocarbonate B (1.10) (6.24 ± 1.08
μM, 5.55 ± 0.88 μM, and 2.34 ± 0.67 μM, against EPG85-
257P, EPG85-257RNOV, and EPG85-257RDB, respectively)
was selected for apoptosis induction studies.
Regarding the pancreatic cancer cell lines, the tested
compounds were less active (Table 3, Table S3, Supporting
Information). Thus, based on IC50 values, only jolkinoate U
(1.8) (8.61 ± 0.58 μM against EPP85-181P; 6.63 ± 0.95 μM
against EPP85-181RNOV; and 5.86 ± 0.07 μM against EPP85-
181RDB) was chosen for further studies.
Annexin V/PI Assay and Active Caspase-3 Assay.
Jolkinoate L (3) showed a remarkable ability to target both
gastric and pancreatic MDR contexts.21 Likewise, jolkinocar-
bonate B (1.10) showed interesting results against gastric cells
and jolkinoate U (1.8) against pancreatic cells (Table 3, Tables
S1 and S2, Supporting Information). Hence, their ability as
apoptosis inducers was evaluated. The annexin V/propidium
iodide (PI) assay was used to assess if compounds 3, 1.8, and
1.10 (30 μM) would induce apoptosis. Caspase activation was
measured with the active caspase-3 assays. Detection of these
events was performed by ﬂow cytometry after 72 h exposure.
The results of total apoptosis (early and late apoptotic events)
and caspase-3 activation were expressed as fold increase (ratio
between treated samples and untreated samples).
Jolkinoate L (3), a triﬂuormethylbenzoyl derivative, induced
apoptosis in the gastric cell lines about 4-fold in EPG85-257P
and EPG85-257RNOV, and created a statistically signiﬁcant 6-
fold induction in EPG85-257RDB (Figure 4A). Through the
caspase-3 data (Figure 4A), it could be concluded that the drug-
induced cytotoxicity occurred via caspase-mediated apoptosis,
since there was a caspase-3 activation of 6−9-fold. On the other
hand, jolkinoate L (3) induced signiﬁcant selective apoptosis in
the pancreatic MDR phenotypes EPP85-181RNOV and
EPP85-181RDB, in about 4.5- and 3.5-fold, respectively (Figure
4B). In the same way as in the gastric cell lines, the apoptotic
process occurred through caspase-3 activation. Remarkable
results were found for EPP85-181RNOV, showing a 12-fold
activation of this apoptosis eﬀector protein (Figure 4B).
Moreover, jolkinocarbonate B (1.10) showed a statistically
signiﬁcant apoptosis induction in the gastric EPG85-257RNOV
cells, but with little apoptosis induction in EPG85-257P or
EPG85-257RDB (Figure 4C). This selective targeting of
EPG85-257RNOV cells was corroborated by the caspase-3
activation data (Figure 4C). Although little apoptosis induction
was detected for EPG85-257P and EPG85-257RDB cells,
caspase-3 activation was taking place (Figure 4C). Therefore, a
quantiﬁable apoptosis induction may occur after 72 h.
The adamantoyl derivative jolkinoate U (1.8) showed
statistically signiﬁcant selective apoptosis induction between
the resistant pancreatic cells (EPP85-181RNOV; EPP85-
181RDB) and the parental cells; with a 5-fold apoptosis
induction on EPP85-181RNOV and a 17-fold induction on
EPP85-181RDB. The observed apoptotic processes were
Figure 4. Induction of apoptosis and activation of caspase-3: (A) jolkinoate L (3) in gastric cells; (B) jolkinoate L (3) in pancreatic cells; (C)
jolkinocarbonate B (1.10) in gastric cells; and (D) jolkinoate U (1.8) in pancreatic cancer cell lines. Total apoptosis was considered the sum of early
and late apoptotic events (cells annexin V positive/PI negative plus cells annexin V positive/PI positive). The results were expressed as the ratio
between treated and untreated samples. Each column represents the mean ± SD (n = 3). Statistical signiﬁcance was calculated for the diﬀerence
between treated resistant cell lines and treated parental cells using a two-tailed unpaired Student’s t test. *, p < 0.05. **, p < 0.01. ***, p < 0.001.
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veriﬁed to proceed via caspase-3 activation, as indicated in
Figure 4D.
■ EXPERIMENTAL SECTION
General Experimental Procedures. See the Supporting
Information.
General Preparation of Derivatives 1.1−1.10 and 2.1−2.4.
The detailed preparation and characterization of the derivatives of
jolkinol D (1.1−1.10) and of jolkinodiol (2.1−2.4) can be accessed in
the Supporting Information.
Rhodamine 123 Accumulation Assay. The mouse T-lymphoma
cells L5178Y (ECACC catalogue no. 87111908, U.S. FDA, Silver
Spring, MD, USA) and the ABCB1-transfected L5178Y mouse T-
lymphoma cells were established and cultured as described.20,38 The
cells were resuspended in serum-free McCoy’s 5A medium in 500 μL
aliquots adjusted of 2 × 106/mL. The lathyrane derivatives were added
at 2 and 20 μM, the positive control verapamil (EGIS Pharmaceuticals
PLC, Budapest, Hungary) at 20 μM, and the solvent control DMSO at
2% (v/v). The incubation of the samples took place at room
temperature for 10 min, after which 10 μL (5.2 μM) of rhodamine-123
was added. The samples were washed twice after incubation at 37 °C
for 20 min, resuspended in phosphate-buﬀered saline (500 μL), and
analyzed by ﬂow cytometry (Partec CyFlow Space instrument, Partec
GmbH, Münster, Germany). The histograms were assessed concern-
ing the mean ﬂuorescence intensity (FL-1), standard deviation, and
peak channel of 20,000 individual cells belonging to the total and gated
populations. The ﬂuorescence activity ratio (FAR) was calculated as
FAR = (L5178Y-MDRFL ‑1 t r e a t e d/L5178Y-MDRFL ‑1c on t r o l)/
(PARFL‑1treated/PARFL‑1control).
ATPase Assay. The SB-MDR1 PREADEASY ATPase Kit
(SOLVO Biotechnology, Szeged, Hungary) was preformed according
to the manufacturer’s instructions. The puriﬁed Sf9 insect membrane
vesicles (4 μg protein/well), expressing high levels of human MDR1,
were incubated in 50 μL of ATPase assay buﬀer, compound, and 2
mM MgATP, for 10 min at 37 °C. The ﬁnal concentration of DMSO
in the experiment was 2% (v/v). The ATPase reaction was stopped,
and the inorganic phosphate (Pi) production was measured colori-
metrically (optical density was read at 630 nm). The amount of Pi
produced is proportional to the ABCB1 activity. Hence, ATPase
activities were determined as the diﬀerence of the measured Pi
liberation with and without the presence of 1.2 mM sodium
orthovanadate (vanadate-sensitive ATPase activity). This ATPase kit
comprises two diﬀerent tests: the activation and inhibition assays.
When the test compound can stimulate the baseline vanadate-sensitive
ATPase activity (activation assay), it reﬂects the ABCB1 transported,
as is the case of verapamil (40 μM), used as positive control. The
inhibition assay assesses the eﬀect of a second transported substrate on
ABCB1 ATPase activity. Thus, the compounds are tested in the
presence of verapamil (40 μM). Inhibitors of ABCB1 may reduce the
verapamil-stimulated vanadate-sensitive ATPase activity. In some
cases, inhibitors may inhibit the baseline transporter ATPase activity
as well, such as cyclosporine A (40 μM), also used as positive control.
Antiproliferative Assay and Drug Combination Studies. The
antiproliferative assay was performed according to a published
procedure.20 The parental (PAR) and multidrug-resistant (MDR)
ABCB1-transfected L5178Y mouse T-lymphoma cells were seeded at 1
× 105/mL and incubated with a concentration gradient of compounds
(ﬁnal volume of 200 μL/well) for 72 h (5% CO2 at 37 °C). The ﬁnal
concentration of DMSO in the experiment was 1% (v/v). Cell growth
was determined by measuring the optical density (OD) at 550 nm (ref
630 nm) with a Multiscan EX ELISA reader (Thermo Labsystems,
Cheshire, WA, USA); and determined as 100 − [(ODsample −
ODmediumcontrol)/(ODcellcontrol − ODmediumcontrol)] × 100. Mean IC50
values were obtained from three independent experiments for each cell
line, by best ﬁtting the dose-dependent inhibition curves in the
GraphPadPrism5 program.
Drug combinations of doxorubicin (Teva) and the compounds were
designed and evaluated according to Chou using the software
CalcuSyn Version 2.34,35 Since the optimal concentration range for
the combination is not known, the most appropriated experimental
design is by using several concentrations of each agent, with data
points above and below IC50. The experimental design followed the
checkerboard microplate method, where dilutions of doxorubicin were
made in a horizontal direction and the dilutions of resistance modiﬁers
vertically in a microtiter plate to a ﬁnal volume of 200 μL of medium
per well. The L5178Y-MDR cells were distributed at 2 × 105 cells/mL
per well and were incubated for 48 h under standard conditions. The
cell growth rate was determined after MTT staining, as previously
described.20 Each drug combination produces an eﬀect, and constant
ratios ([compound]/[doxorubicin]) can be taken from the diagonals
of the checkerboard. The eﬀect of each constant ratio across a
concentration gradient was computed in CalcuSyn software. More
details concerning the CalcuSyn model and combination index
calculation can be assessed in the Supporting Information.
Collateral Sensitivity Assays: Antiproliferative Assay. Cell
culture procedures of the human carcinoma cell lines (EPG85-257P
and EPP85-181P) and their drug-resistant sublines (EPG85-
257RNOV, EPG85-257RDB, EPP85-181RNOV, EPP85-181RDB)
have been described previously.21 Brieﬂy, 5 × 103/mL (EPG85-257P
and EPP85-181P) and 7.5 × 103/mL (EPG85-257RNOV, EPG85-
257RDB, EPP85-181RNOV, EPP85-181RDB) were seeded. After
attachment (48 h), the compounds were added in a dilution series for
incubation during 5 days (5% CO2 at 37 °C). The ﬁnal concentration
of DMSO in the experiment was 0.3% (v/v). Cell growth was based on
sulforhodamine B (SRB) staining and was performed according to a
published procedure.21 Cell growth was measured at 562 nm against
the reference wavelength of 690 nm. Mean IC50 values were obtained
from three to four independent experiments in triplicate for each cell
line, by best ﬁtting the dose-dependent inhibition curves in the
GraphPadPrism5 program. Relative resistance (RR) values were
calculated as IC50(resistant cells)/IC50(parental cells).
Annexin V/PI Staining and Active Caspase-3 Assay. An FITC
Annexin V apoptosis detection kit (BD Pharmingen, BD Biosciences)
was used to detect cytotoxic drug-induced apoptosis. The intracellular
presence of active caspase-3 was detected using an FITC Active
Caspase-3 Apoptosis Kit (BD Pharmingen, BD Biosciences). Both
assays followed the same experimental design. Brieﬂy, 6 × 104 cell/mL
of parental cell lines (EPG85-256P and EPP85-181P) and 1 × 105
cell/mL of resistant cell lines (EPG85-256RNOV, EPG85−256RDB,
EPP85-181RNOV, and EPP85-181RDB) were seeded in six-well
plates in complete medium and attached for 24 h. The medium was
thrown away the next day, and new medium (with 30 μM of
compounds) was added to the cancer cells. The ﬁnal concentration of
DMSO in the experiment was 0.3% (v/v). Camptothecin (Cayman
Chemicals, Ann Arbor, Michigan, USA) was used as positive control
(1 μM). Cells were further incubated for 72 h (5% CO2, 37 °C). The
concentration of compounds and positive control, and incubation time
were optimized in order to ensure a good sampling for ﬂow cytometry
measurement of the apoptotic process (data not shown). After this
incubation period, cells were trypsinized, washed in PBS, and stained
according to each kit manufacturer’s instructions. Stained cells were
analyzed using a BD Accuri C6 ﬂow cytometer (BD Pharmingen, BD
Biosciences), and data were processed with BD Accuri C6 software.
Each sample was assessed using a collection of 10 000 events. The
mean values and standard deviations were calculated from three
independent experiments.
Statistical Analysis. K-means clustering, which subdivides the
compounds (those with the nearest mean) into groups that exhibit a
high degree of similarity, was performed with Tanagra, version 1.4.41
(https://eric.univ-lyon2.fr/~ricco/tanagra/). Statistical evaluation of
the apoptosis assays data was performed with the two-tailed unpaired
Student’s t test using GraphPadPrism5 software. Probability value p <
0.05 was considered statistically signiﬁcant.
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